Combined antiangiogenic gene therapy with sflt and endostatin is highly effective in a rat model of hepatocellular carcinoma
F Graepler, B Verbeek, T Gräter, I Smirnow, HL Kong, D Schuppan, M Wehrmann, M Gregor, UM Lauer · Zeitschrift für Gastroenterologie · 2004 · Heft 08
Bibliografische Angaben
Zusammenfassung
The multiplicity of regulators acting in the process of tumor angiogenesis offers diverse molecular targets for an antiangiogenic therapy. On the other hand, therapeutical attempts to antagonize one of these players could be equalized by upregulation of another proangiogenic factor leading to some kind of resistance to antiangiogenic therapy. A combination therapy addressing two or more angiogenic targets could therefore be useful. Growth of Hepatocellular carcinoma, an uncurable disease in most cases so far, is supposed to be a suitable target for antiangiogenic therapy. We tested the effects of expression of e…
